Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.
Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.